

## Identifying patients

1. Determine if patient is experiencing [chronic or acute pain](#) and establish a diagnosis supported by diagnostic studies. If patient is experiencing acute pain, refer to the [Safe Prescribing for Acute Pain toolkit](#).
2. **Review medical history**, including records from previous providers before prescribing. Check [CURES](#) prior to prescribing schedule II-IV medications and every four months thereafter as long as the medication is part of the patients' treatment, per [Health and Safety Code section 11165.4\(a\)\(1\)\(A\)\(i\)](#).
3. Determine if patient is exhibiting [signs of opioid use disorder \(OUD\)](#). Use these tips for [assessing for opioid use disorder](#) to develop a care plan.
4. **Assess patient's risk of future opioid misuse** or abuse using validated screening tools such as [ORT](#) or [SBIRT](#).
5. Have patient fill out a [pre-visit questionnaire](#) to identify [changes in functional or behavioral factors](#) that would affect the treatment plan.

**Statement on co-prescribing Naloxone:** [Co-prescribing Naloxone](#) is strongly recommended with any opioid prescription to prevent opioid overdose and begin a conversation with patients regarding the risks involved in opioid therapy. As of January 1, 2019, [Assembly Bill No. 2760](#) requires prescribers to offer naloxone to patients considered to be at high risk of overdose including patients on 90 Morphine Milligram Equivalents (MME) per day, patients prescribed benzodiazepines along with opioids, and patients that present to prescribers as having an increased risk of overdose. Prescribers are also required to provide education on overdose prevention and the use of naloxone for the complete or partial reversal of opioid overdose to one or more persons designated by the patient, or if the patient is a minor, to the minor's parent or guardian. For more information about this requirement, please consult with your local liability carrier or local county medical society.

## If your patient has or may have opioid use disorder

- Utilize [communication strategies](#) to avoid the stigmatizing language strongly associated with opioid use disorder
- Evaluate the risks and benefits of continued chronic opioid treatment
- Strongly consider treatment for OUD that includes [medication assisted treatment \(MAT\)](#)
- Educate patients on the short term and long term benefits of [tapering off opioids](#) and transitioning to [non-opioid pain management](#) and recommended [alternatives](#) provided by the Centers for Disease Control and Prevention
- Refer patients with OUD for MAT when necessary
  - » [California American College of Emergency Physicians](#) offers resources for addressing MAT services in the Emergency department
  - » Refer patient to a treatment program by utilizing [SAMHSA](#), [Sam's Resources](#), or [2-1-1 Monterey County](#) to locate the best treatment facility
  - » Buprenorphine treatment practitioner [locator](#) helps locate practitioners with a valid x-waiver who can assist with MAT
  - » [Guide](#) for patients beginning Buprenorphine treatment at home
  - » UCSF Clinician Consultation Center [substance use management](#) offers clinician to clinician telephone consultations focusing on substance use evaluation and management for providers
  - » Check [CURES](#)
- Educate patients on the merits of MAT for the treatment of OUD
- [Co-prescribing Naloxone](#) is particularly important to consider for patients with OUD due to their increased risk of overdose

## If patient is already engaged in long-term opioid pain reduction therapy

- Assess functional improvement on opioids (with a validated tool such as [PEG](#)), and compare results to baseline function and pain
- Consider referral to [pain management specialist/physiatry](#) for adjunctive interventions and procedures
- Use patient [communication strategies](#) to avoid stigmatizing language, and more effectively discuss transitioning to [non-opioid alternatives](#) or [alternative](#) therapies to decrease discomfort
- Educate patient on the [evidence](#) supporting short-term and long-term benefits of [tapering off opioids](#) and transitioning to [non-opioid pain management](#)
- Continue [co-prescribing Naloxone](#) with any long-term opioid prescription
- Consider using [patient agreement contracts](#) as a tool to discuss risks and responsibilities of continued opioid therapy
- Consider periodic urine toxicology monitoring to assess for adherence to prescribed medications and for other substance use on a monthly, or quarterly basis
- Continually [reassess](#) for worrisome behaviors and side effects
- Track conditions that increase risks of opioid therapy such as age, cognitive status, respiratory status, other prescriptions, and personal/family history of substance use disorder
- Review tips for [assessing for opioid use disorder](#), and the [aberrant drug-taking behaviors information sheet](#) to monitor for signs of [opioid use disorder \(OUD\)](#)
- Be aware of [Medical Board of California](#) and [Centers for Disease Control](#) guidelines on high-risk MME dosages and evaluate risks and benefits of continuing opioid therapy at greater than 50 MME per day
- Use extreme caution with [concomitant prescription of opioids with benzodiazepines](#) or other sedatives

## Prior to considering initiating long term opioid therapy

- Perform a physical exam to determine baseline function and pain
- Perform warranted imaging and consider consultation with [pain management or physiatry](#) to evaluate root cause of pain prior to initiation of pharmaceuticals (referral appropriate prior to initiation of opiates and prior to surgical referral in the vast majority of cases).
- Educate patients on the [evidence](#) supporting the benefits of using [non-pharmacological](#) pain management adjuncts
- Be aware that clinical trials show that opioids are not more effective in controlling chronic pain than non-opioid modalities
- Create a plan of treatment with the patient that incorporates non-opioid interventions as much as possible
- Consider starting with a few days' supply while documenting, then bring patient back for in-depth discussion and [history review](#) at follow-up appointment
- Consider using [patient agreement contracts](#) as a tool to discuss risks and responsibilities of opioid therapy
- Track conditions that [increase risks](#) of opioid therapy such as age, cognitive status, respiratory status, and other prescriptions
- Discuss an [opioid therapy](#) exit plan with patients
- Conduct a urine toxicology screen prior to initiating opioid therapy

**Website links and additional resources can be found at [chomp.org/prescribesafe](http://chomp.org/prescribesafe)**